Immunohistochemical evaluations of primary tumor tissues from breast, colon, hepatocellular and prostate cancer patients illustrate that loss of or reduction in WNT5A protein expression correlates with shorter recurrence-free survival and thus poor prognosis [1,2,6,7,8]. Here, WNT5A is linked to prostate cancer.